REPL
Price
$9.27
Change
-$0.22 (-2.32%)
Updated
Jun 20 closing price
Capitalization
714.59M
38 days until earnings call
XNCR
Price
$8.54
Change
+$0.18 (+2.15%)
Updated
Jun 20 closing price
Capitalization
607.8M
37 days until earnings call
Interact to see
Advertisement

REPL vs XNCR

Header iconREPL vs XNCR Comparison
Open Charts REPL vs XNCRBanner chart's image
Replimune Group
Price$9.27
Change-$0.22 (-2.32%)
Volume$1.47M
Capitalization714.59M
Xencor
Price$8.54
Change+$0.18 (+2.15%)
Volume$1.65M
Capitalization607.8M
REPL vs XNCR Comparison Chart in %
Loading...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
REPL vs. XNCR commentary
Jun 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REPL is a Hold and XNCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2025
Stock price -- (REPL: $9.27 vs. XNCR: $8.54)
Brand notoriety: REPL and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REPL: 118% vs. XNCR: 177%
Market capitalization -- REPL: $714.59M vs. XNCR: $607.8M
REPL [@Biotechnology] is valued at $714.59M. XNCR’s [@Biotechnology] market capitalization is $607.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $326.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REPL’s FA Score shows that 1 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • REPL’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, both REPL and XNCR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REPL’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 3 bullish TA indicator(s).

  • REPL’s TA Score: 5 bullish, 4 bearish.
  • XNCR’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, REPL is a better buy in the short-term than XNCR.

Price Growth

REPL (@Biotechnology) experienced а -5.21% price change this week, while XNCR (@Biotechnology) price change was -7.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.57%. For the same industry, the average monthly price growth was +27.78%, and the average quarterly price growth was +14.34%.

Reported Earning Dates

REPL is expected to report earnings on Jul 31, 2025.

XNCR is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+9.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($715M) has a higher market cap than XNCR($608M). REPL YTD gains are higher at: -23.452 vs. XNCR (-62.837). XNCR has higher annual earnings (EBITDA): -161.68M vs. REPL (-235.43M). REPL (484M) and XNCR (470M) have equal amount of cash in the bank . XNCR has less debt than REPL: XNCR (67.8M) vs REPL (76.2M). XNCR has higher revenues than REPL: XNCR (127M) vs REPL (0).
REPLXNCRREPL / XNCR
Capitalization715M608M118%
EBITDA-235.43M-161.68M146%
Gain YTD-23.452-62.83737%
P/E RatioN/AN/A-
Revenue0127M-
Total Cash484M470M103%
Total Debt76.2M67.8M112%
FUNDAMENTALS RATINGS
REPL vs XNCR: Fundamental Ratings
REPL
XNCR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
5865
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for XNCR (79). This means that REPL’s stock grew somewhat faster than XNCR’s over the last 12 months.

REPL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as XNCR (100). This means that REPL’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as REPL (98). This means that XNCR’s stock grew similarly to REPL’s over the last 12 months.

REPL's Price Growth Rating (58) in the Biotechnology industry is in the same range as XNCR (65). This means that REPL’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for REPL (100). This means that XNCR’s stock grew significantly faster than REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REPLXNCR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
69%
Momentum
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 17 days ago
77%
Bullish Trend 3 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 6 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
67%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WEECX11.010.01
+0.09%
TETON Westwood Equity A
JDEUX43.94-0.10
-0.23%
JPMorgan US Research Enhanced Equity R6
SGAPX23.65-0.11
-0.46%
Virtus SGA Global Growth I
TINVX23.99-0.17
-0.70%
Thornburg International Growth R4
INDCX12.46-0.11
-0.88%
Victory Pioneer Disciplined Growth C

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with ELVAF. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
-2.32%
ELVAF - REPL
60%
Loosely correlated
N/A
SNDX - REPL
51%
Loosely correlated
-2.17%
IDYA - REPL
51%
Loosely correlated
-0.87%
XNCR - REPL
50%
Loosely correlated
+2.15%
CGON - REPL
46%
Loosely correlated
-2.78%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with CRNX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
+2.15%
CRNX - XNCR
59%
Loosely correlated
N/A
BEAM - XNCR
57%
Loosely correlated
-1.35%
KRYS - XNCR
55%
Loosely correlated
+0.28%
BCYC - XNCR
54%
Loosely correlated
N/A
SYRE - XNCR
54%
Loosely correlated
-0.46%
More